These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24852431)

  • 21. Impact of catechol-O-methyltransferase gene variants on methylation status of P16 and MGMT genes and their downregulation in colorectal cancer.
    Wani HA; Majid S; Bhat AA; Amin S; Farooq R; Bhat SA; Naikoo NA; Beigh MA; Kadla SA
    Eur J Cancer Prev; 2019 Mar; 28(2):68-75. PubMed ID: 30379684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of epigenetic silencing of the SFRP2 gene in colorectal cancer as a clinical biomarker and molecular significance.
    Boughanem H; Pilo J; García-Flores LA; Arranz I; Ramos-Fernandez M; Ortega-Castan M; Crujeiras AB; Sandoval J; Macias-Gonzalez M
    J Transl Med; 2024 May; 22(1):509. PubMed ID: 38802858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for genomic fragments that are methylated specifically in colorectal carcinoma with a methylated MLH1 promoter.
    Koinuma K; Kaneda R; Toyota M; Yamashita Y; Takada S; Choi YL; Wada T; Okada M; Konishi F; Nagai H; Mano H
    Carcinogenesis; 2005 Dec; 26(12):2078-85. PubMed ID: 16033773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer.
    Mrkonjic M; Roslin NM; Greenwood CM; Raptis S; Pollett A; Laird PW; Pethe VV; Chiang T; Daftary D; Dicks E; Thibodeau SN; Gallinger S; Parfrey PS; Younghusband HB; Potter JD; Hudson TJ; McLaughlin JR; Green RC; Zanke BW; Newcomb PA; Paterson AD; Bapat B
    PLoS One; 2010 Oct; 5(10):e13314. PubMed ID: 20967208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MLH1 region polymorphisms show a significant association with CpG island shore methylation in a large cohort of healthy individuals.
    Savio AJ; Lemire M; Mrkonjic M; Gallinger S; Zanke BW; Hudson TJ; Bapat B
    PLoS One; 2012; 7(12):e51531. PubMed ID: 23240038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MLH1 promoter methylation, diet, and lifestyle factors in mismatch repair deficient colorectal cancer patients from EPIC-Norfolk.
    Gay LJ; Arends MJ; Mitrou PN; Bowman R; Ibrahim AE; Happerfield L; Luben R; McTaggart A; Ball RY; Rodwell SA
    Nutr Cancer; 2011; 63(7):1000-10. PubMed ID: 21875327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
    Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
    Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
    Alemayehu A; Sebova K; Fridrichova I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of methylation-associated silencing of formin 2 in colorectal carcinogenesis.
    Li DJ; Feng ZC; Li XR; Hu G
    World J Gastroenterol; 2018 Nov; 24(44):5013-5024. PubMed ID: 30510376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas.
    Psofaki V; Kalogera C; Tzambouras N; Stephanou D; Tsianos E; Seferiadis K; Kolios G
    World J Gastroenterol; 2010 Jul; 16(28):3553-60. PubMed ID: 20653064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
    Ye C; Shrubsole MJ; Cai Q; Ness R; Grady WM; Smalley W; Cai H; Washington K; Zheng W
    Oncol Rep; 2006 Aug; 16(2):429-35. PubMed ID: 16820927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of hMLH1/hMSH2 gene mutations and hMLH1 promoter methylation in sporadic colorectal cancer.
    Wang Y; Li D; Li X; Teng C; Zhu L; Cui B; Zhao Y; Hu F
    Med Oncol; 2014 Jul; 31(7):39. PubMed ID: 24990217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoter methylation and immunohistochemical expression of hMLH1 and hMSH2 in sporadic colorectal cancer: a study from India.
    Malhotra P; Anwar M; Kochhar R; Ahmad S; Vaiphei K; Mahmood S
    Tumour Biol; 2014 Apr; 35(4):3679-87. PubMed ID: 24317816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families.
    Zhou HH; Yan SY; Zhou XY; Du X; Zhang TM; Cai X; Lu YM; Cai SJ; Shi DR
    World J Gastroenterol; 2008 Dec; 14(48):7329-34. PubMed ID: 19109866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer.
    Zhang H; Zhu YQ; Wu YQ; Zhang P; Qi J
    World J Gastroenterol; 2014 May; 20(20):6329-35. PubMed ID: 24876755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
    Xu XL; Yu J; Zhang HY; Sun MH; Gu J; Du X; Shi DR; Wang P; Yang ZH; Zhu JD
    World J Gastroenterol; 2004 Dec; 10(23):3441-54. PubMed ID: 15526363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
    Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
    BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study.
    Jensen LH; Rasmussen AA; Byriel L; Kuramochi H; Crüger DG; Lindebjerg J; Danenberg PV; Jakobsen A; Danenberg K
    Cell Oncol (Dordr); 2013 Oct; 36(5):411-9. PubMed ID: 24027018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer.
    de Vogel S; Wouters KA; Gottschalk RW; van Schooten FJ; de Goeij AF; de Bruïne AP; Goldbohm RA; van den Brandt PA; Weijenberg MP; van Engeland M
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3086-96. PubMed ID: 19843671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.